You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Solving Sepsis: Early Identification and Prompt Management Using Machine Learning

    SBC: Cohere-Med, Inc.            Topic: 300

    Abstract This fast-track STTR application proposes to enhance, validate, and scale Sepsis Watch, a deep learning sepsis detection and management system built using data from the Emergency Department (ED) Duke University Hospital (DUH). The proposal will extend and enhance Sepsis Watch to EDs, general inpatient wards, and intensive care unit (ICU) settings across multiple health systems in the Unit ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes

    SBC: VALA SCIENCES, INC.            Topic: NHLBI

    Cardiotoxicity is a leading cause of drug discovery attrition across all of preclinical and clinical drug discovery. While the FDA and the Comprehensive in vitro Proarrhythmia Assay initiative (CiPA) are focused primarily on predicting proarrhythmic effects, drug attrition due to cardiomyopathy, or primary cardiac cytotoxicity, may be even more prevalent, is typically currently only carried out vi ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Wearable Fluorescence Imaging Device for IntraoperativeIdentification of Brain Tumors

    SBC: BIOPTICS TECHNOLOGY LLC            Topic: 102

    ABSTRACT Approximately 700,000 people in the United States are diagnosed with a primary brain tumor. Of these, malignant gliomas (MGs) account for approximately 40% of all intracranial tumors, with an overall survival rate of only ~34%. Surgical resection remains the cornerstone of therapy and the extent of resection correlates with survival. Fluorescence imaging has emerged as an adjunctive techn ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Automated Mental Health Referral System

    SBC: MiResource, Inc.            Topic: 104

    This proposal addresses a significant barrier to obtaining treatment for college-ageyouth with mental disorders. Many college-age youth with impairing mental disordersremain untreated because of concerns about stigma and privacy, inconvenience and wait times, andbecause universities are often unable to service all such students. Also, of critical importance,when referral for treatment is implement ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension

    SBC: AQUALUNG THERAPEUTICS, CORP            Topic: NHLBI

    ABSTRACT Pulmonary arterial hypertension (PAH) is a fatal disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A1 R42 Fast Track STTR application focuses on eNAMPT (extra- cellular nicotinamide phosphoribosyltransferase) as a novel, highly attractive PAH target. Aqualung Therapeutics has developed a humanized eNAMPT-neutralizing mAb, ALT-10 ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. A digital tool for monitoring speech decline in ALS

    SBC: MODALITY.AI , INC            Topic: NIDCD

    PROJECT SUMMARY Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease resulting in the progressive loss of limb, trunk, and head and neck (bulbar) motor function and is the most common adult-onset motor neuron disease. The disease is characterized by significant across-patient heterogeneity in the onset region and in pattern and progression rate, making early and accurate diagno ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Endovascular ChemoFilter to Reduce Doxorubicin Toxicity during Intra-Arterial Chemotherapy

    SBC: FILTRO MEDICAL INC.            Topic: 102

    PROJECT SUMMARYDosing of chemotherapeutics is limited by systemic toxic side effects. We are developing a new class of image- guided temporarily deployable, endovascular catheter-based medical devices that selectively remove specific drugs from the blood stream to reduce systemic toxicities. The proposed ChemoFilters incorporate specialized materials that bind target drugs in situ through a variet ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. I-RED Southeast XLerator Network

    SBC: XLERATEHEALTH, LLC            Topic: 500

    Project Summary I-RED Southeast XLerator Network, powered by XLerateHealth, LLC in collaboration with the University of Kentucky as the lead academic partner institution, proposes to develop a suite of experience-based entrepreneurship education products and commercialization education tools to address the needs of academic institutions and their faculty, researchers, innovators, and graduate/unde ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity

    SBC: AQUALUNG THERAPEUTICS, CORP            Topic: 300

    ABSTRACT Inflammatory bowel disease (IBD) is a debilitating disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A0 R42 STTR application focuses on a highly novel humanized monoclonal antibody (mAb), ALT-100, to target and neutralize eNAMPT (extracellular nicotinamide phosphoribosyltransferase), a damage-associated molecular pattern protein ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease

    SBC: Hillhurst Biopharmaceuticals, Inc.            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT The goal of the proposed project is to evaluate the clinical potential of HBI-002, a novel oral low dose carbon monoxide (CO) drug product, that enables the use of low dose CO to prevent Vaso-Occlusive Crises (VOCs) in Sickle Cell Disease (SCD). Numerous studies, both preclinical and clinical, demonstrate that CO has dual mechanisms of action including anti-sickling and an ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government